Finnish CurifyLabs Raises €6.7M to Replace Manual Compounding With Robotic Drug Manufacturing

CurifyLabs, a Finnish healthtech company, has raised €6.7 million to expand its automated solution for manufacturing compounded medications. The round was led by Springvest, a Finnish investment platform, and includes a €1 million deep tech loan from Business Finland. The funds will be used to scale the company’s operations and secure high-volume customers, including in the United States.

Founders Charlotta Topelius (CEO) and Niklas Sandler Topelius (CTO)

Compounded medications—customized drugs prepared when standard formulations do not meet individual needs—are essential for patients with allergies, unusual dosage requirements, or swallowing difficulties. These include pediatric patients and those with cancer. According to the company, "50% of medicines are not available in doses or formulations approved for children" and only "1% of drugs are personalized through compounding" (FDA), despite growing demand driven by aging populations, chronic diseases, and supply chain disruptions. The global compounding market is reportedly worth €15 billion, with an annual growth rate of 5.5%.

Formulation preparation performed by CurifyLabs' pharmaceutical specialists

CurifyLabs’ technology replaces traditional manual compounding, which involves measuring and mixing ingredients by hand, with an integrated system combining excipient bases, active pharmaceutical ingredients, a robotic dispenser, and cloud-based guidance. The company claims its system makes the compounding process "four times faster" and "enables limitless dosing flexibility".

The company’s platform includes the Pharma Printer, a desktop robot that creates personalized tablets or liquids by combining raw ingredients or crushed tablets with proprietary excipient bases. A cloud-based formulation library assists pharmacists through validated procedures, with integrated quality control to ensure mass uniformity.

The CurifyLabs Pharma Printer, a CE-marked laboratory device that produces tablets in 1–2 seconds, with in-process quality control and validated cleaning procedures.

In parallel, CurifyLabs is coordinating RoboPharma, a €5.6 million project funded under the EU4Health program. The initiative brings together six European partners to develop an AI- and robotics-driven pharmaceutical production platform for decentralized, point-of-care manufacturing. The goal is to improve Europe’s preparedness for crises such as pandemics or natural disasters by allowing hospitals and community pharmacies to produce essential drugs on demand.

CEO Charlotta Topelius said:

“Automated manufacturing of personalized medicine will provide better medication safety for patients and help pharmacies lower operating costs. We are going to see a major paradigm shift in the manufacturing of personalized medicine, driven by aging populations, chronic diseases, supply chain disruptions, patient demand, and other factors.”

CurifyLabs has raised €17.6 million to date and operates offices in Finland, Germany, and the United States. Its CTO and co-founder, Niklas Sandler, is a professor of pharmaceutical technology at Åbo Akademi University and brings several decades of pharmaceutical experience to the team. He previously served as Chief Technology Officer at Nanoform, where he led the development of the company’s nanoparticle engineering platform. Prior to this, Sandler held senior scientist roles at AstraZeneca, focusing on late-stage pharmaceutical product development and material science projects.

Topics: Startups & Deals